Antimicrobial Use, Regulatory Policies, and Resistance Challenges in Brazil: A Pharmacoepidemiological Overview with Implications for Comparable Settings

Background/Objectives: Antimicrobial resistance (AMR) is one of the most critical global public health challenges, particularly in low- and middle-income countries where antimicrobial consumption remains high. Brazil has historically exhibited elevated antimicrobial consumption in community settings, despite progressive regulatory interventions over the past decade. This article provides a pharmacoepidemiological overview of antimicrobial use, regulatory measures, and resistance-related challenges in Brazil, with implications for comparable settings. Methods: A narrative review was conducted using PubMed/MEDLINE, Scopus, and SciELO, covering publications from January 2010 to December 2025 and restricted to English- and Portuguese-language sources. Official data from the National System for the Management of Controlled Products (SNGPC), ANVISA bulletins, BR-GLASS reports, and national AMR surveillance initiatives were also incorporated. Results: Between 2014 and 2021, 355.7 million antimicrobial sales records were captured in the SNGPC (of 532.5 million controlled-product records; 2014 to November 2021). Amoxicillin (24.1%), azithromycin (12.2%), ciprofloxacin (9.4%), and cephalexin (7.7%) were the best-selling agents, and the top ten accounted for 76.5% of antimicrobial sales. DDD-based consumption increased by approximately 30% from 2014 to 2019, and 24 of 53 systemic antimicrobials (45%) were classified as WHO Watch, and Watch accounted for 45.5–49.9% of DDD-based consumption across regions in 2019. The COVID-19 pandemic was temporally associated with a 152% increase in azithromycin consumption (from 1.40 to 3.53 DDD/1000 inhabitants/day between February and July 2020). Carbapenem resistance in Klebsiella pneumoniae increased from 26% to 52% and remained elevated afterwards; this temporal association does not establish causality. Among Brazilian hospitals with adult intensive care units, fewer than 50% had a formal antimicrobial stewardship program. Conclusions: Regulatory measures have strengthened prescription requirements and reduced non-prescription sales; however, their impact on inappropriate clinical use and resistance trends remains heterogeneous. Strengthening antimicrobial stewardship, improving microbiological diagnostic capacity, and integrating surveillance systems are essential priorities for mitigating AMR in Brazil and in comparable healthcare settings.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-11-16
DOI
https://doi.org/10.3390/antibiotics15111143
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antimicrobial Use, Regulatory Policies, and Resistance Challenges in Brazil: A Pharmacoepidemiological Overview with Implications for Comparable Settings

Márcio Miranda Brito, Marco Aurélio Gondim Cordeiro, Maria Pantoja Moreira de Sena, Eduardo Saavedra Sanchez et al.
4 links
Antibiotics
Antibiotic Use and Resistance
article

Antimicrobial Use, Regulatory Policies, and Resistance Challenges in Brazil: A Pharmacoepidemiological Overview with Implications for Comparable Settings

Márcio Miranda Brito, Marco Aurélio Gondim Cordeiro, Maria Pantoja Moreira de Sena, Eduardo Saavedra Sanchez, Sávia Denise Silva Carlotto Herrera, Taides Tavares dos Santos, Talissa Bandeira Santos, I Made Dwi Mertha Adnyana, Maykon Jhuly Martins de Paiva, Flávio Ricardo Silva Sousa, Sílvia Minharro, Jorgete Carneiro Chaves, Luann Wendel Pereira de Sena, José Luiz Fernandes Vieira, Renata Ferreira Diogo de Paiva, José Vinicius Dos Anjos NASCIMENTO, Rejanne Lima ARRUDA, Emmeline de Sá Rocha, Yslla Milla de Souza Alencar, Raísa Silva dos Santos, Necy Kawamura de Lacerda Marçal, Allana Nascimento Delgado Mota, Carolina Heitmann Mares Azevedo Ribeiro
article en

Abstract

Background/Objectives: Antimicrobial resistance (AMR) is one of the most critical global public health challenges, particularly in low- and middle-income countries where antimicrobial consumption remains high. Brazil has historically exhibited elevated antimicrobial consumption in community settings, despite progressive regulatory interventions over the past decade. This article provides a pharmacoepidemiological overview of antimicrobial use, regulatory measures, and resistance-related challenges in Brazil, with implications for comparable settings. Methods: A narrative review was conducted using PubMed/MEDLINE, Scopus, and SciELO, covering publications from January 2010 to December 2025 and restricted to English- and Portuguese-language sources. Official data from the National System for the Management of Controlled Products (SNGPC), ANVISA bulletins, BR-GLASS reports, and national AMR surveillance initiatives were also incorporated. Results: Between 2014 and 2021, 355.7 million antimicrobial sales records were captured in the SNGPC (of 532.5 million controlled-product records; 2014 to November 2021). Amoxicillin (24.1%), azithromycin (12.2%), ciprofloxacin (9.4%), and cephalexin (7.7%) were the best-selling agents, and the top ten accounted for 76.5% of antimicrobial sales. DDD-based consumption increased by approximately 30% from 2014 to 2019, and 24 of 53 systemic antimicrobials (45%) were classified as WHO Watch, and Watch accounted for 45.5–49.9% of DDD-based consumption across regions in 2019. The COVID-19 pandemic was temporally associated with a 152% increase in azithromycin consumption (from 1.40 to 3.53 DDD/1000 inhabitants/day between February and July 2020). Carbapenem resistance in Klebsiella pneumoniae increased from 26% to 52% and remained elevated afterwards; this temporal association does not establish causality. Among Brazilian hospitals with adult intensive care units, fewer than 50% had a formal antimicrobial stewardship program. Conclusions: Regulatory measures have strengthened prescription requirements and reduced non-prescription sales; however, their impact on inappropriate clinical use and resistance trends remains heterogeneous. Strengthening antimicrobial stewardship, improving microbiological diagnostic capacity, and integrating surveillance systems are essential priorities for mitigating AMR in Brazil and in comparable healthcare settings.

AntibioticsVol. 15(11)
Universitas Jambi (ID), Royal Society of Tropical Medicine and Hygiene (GB), Universidade Federal do Sul e Sudeste do Pará (BR), Universidade Federal do Tocantins (BR), Universidade Federal do Norte do Tocantins (BR), University of Gurupi (BR), Universidade Federal do Pará (BR)
Good health and well-being
Antibiotic Use and Resistance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon